Actively Recruiting
Prospective, Double Blind, Randomized Control Trial Comparing the Efficacy of Intra-articular Injections for the Treatment of Primary Glenohumeral Osteoarthritis
Led by Rush University Medical Center · Updated on 2026-02-17
200
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness of two types of injections—intra-articular corticosteroid injections and platelet-rich plasma (PRP) injections—for treating primary glenohumeral osteoarthritis, a form of arthritis affecting the shoulder joint. This trial aims to understand how these commonly used treatments compare in providing symptom relief and potentially delaying or preventing the need for shoulder replacement surgery. The study is a prospective, double-blind, randomized controlled trial sponsored by Rush University Medical Center. Participants will be randomly assigned to receive either an ultrasound-guided injection of 80mg Depo-Medrol with 8cc Lidocaine or an ultrasound-guided injection of PRP prepared from a 15cc blood draw processed using the Arthrex Autologous Conditioned Plasma kit. Each participant will receive only one injection during the study. The trial does not include a placebo group but compares these two active treatments directly. During the study, participants will be monitored for pain relief using the Visual Analog Scale (VAS) at 12 weeks after injection. Researchers will assess how each treatment impacts pain levels over this period. The study includes careful screening based on medical history and previous treatments, and participants will be followed according to the trial schedule to evaluate outcomes and safety. The total duration of participation varies by individual needs.
CONDITIONS
Brief Title
Efficacy of Intra-articular Injections for the Treatment of Primary Glenohumeral Osteoarthritis(GHOA)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient 18 years of age or older
- Diagnosed with primary glenohumeral arthritis confirmed by radiographs and clinical evaluation
- Baseline shoulder pain level greater than 4 on the Visual Analog Scale
You will not qualify if you...
- Secondary causes of arthritis such as septic arthritis, rheumatoid arthritis, rotator cuff arthropathy, or post-traumatic arthritis
- Shoulder surgery on the same side within the past year
- Any injection into the same shoulder joint within the last 3 months
- Allergy to lidocaine
- Known pregnancy
- Current workers compensation case related to the shoulder
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single treatment session
Participants receive a single ultrasound-guided intra-articular injection of either corticosteroid or platelet-rich plasma as part of the study.
1 visit (in-person)
Duration - 12 weeks
Participants are monitored for 12 weeks after the injection to assess pain levels and treatment efficacy.
Follow-up visits as scheduled up to 12 weeks
Trial Site Locations
Total: 1 location
1
Rush University Medical Center
Chicago, Illinois, United States, 60612
Actively Recruiting
Research Team
C
Carla M Edwards, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here